S1P1 agonist 7

S1P1 agonist 7 is a potent, orally active, and β-arrestin-biased S1P1 agonist (EC50 (G‑protein) = 12.7 nM and EC50 (β‑arrestin) = 3.23 nM) . S1P1 agonist 7 demonstrates potent immunomodulatory activity and a favorable safety profile. S1P1 agonist 7 exhibits excellent metabolic stability, minimal to moderate CYP inhibition, and S1P3-sparing selectivity. S1P1 agonist 7 shows pharmacokinetics, effectively reduces circulating lymphocytes, and significantly alleviates disease severity in experimental autoimmune encephalomyelitis (EAE) mouse models under both prophylactic and therapeutic regimens. S1P1 agonist 7 can be used for multiple sclerosis (MS) research[1].